Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford’s Pandemic Sciences Institute (PSI) has been formally launched at a two-day event at the Blavatnik School of Government, at which the lead researchers set out its direction and strategy for the next five years.

University of Oxford

The Institute will harness the University’s research excellence as well as its global research collaborations and partnerships developed over decades between academia, industry and governments – many of whom were represented at the PSI launch, including Dr Jenny Harries and Patrick Vallance.

It will draw together academics and experts from across the University to build a multi-disciplinary institute focused on reducing the risk from infectious threats through science, innovation and building global preparedness.

The PSI’s underlying mission will be to create collaborative solutions to infectious disease threats, bringing together fundamental and translational research to improve global health and enhance real-world capabilities to respond to future outbreaks.

Professor Sir Peter HorbyProfessor Sir Peter HorbySpeaking at the launch, Professor Sir Peter Horby, Moh Family Foundation Professor of Emerging Infections and Director of the Pandemic Sciences Institute, said: ‘During the COVID pandemic, diagnostic tests, drugs and vaccines were developed and deployed at speeds that were previously unthinkable, and we benefited from remarkable insights into epidemiology, biology and behaviour in near real time.

‘The Pandemic Sciences Institute aims to make such exceptional achievements routine and ensure the benefits are shared by all. We believe that we can make the world a safer place for everyone by uniting disciplines and sectors to tackle complex infectious disease threats together.’

 

Dame Sarah Gilbert, Saïd Professor of VaccinologyDame Sarah Gilbert, Saïd Professor of Vaccinology

Other speakers at the event included Dame Sarah Gilbert, Saïd Professor of Vaccinology, and Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group, who discussed how the COVID-19 pandemic had a positive impact on collaborative efforts to develop a vaccine against the disease, and what the future holds for overall vaccine development.

Professor Miles Carroll, Head of High Consequence Emerging Viruses, explained why understanding pathogens is important in developing both non-pharmaceutical and pharmaceutical interventions, as well as how partnerships with national and international organisations as well as low- to middle-income countries are key to containing dangerous pathogens.

The importance of embedding programmes of research in ethics, social and behavioural sciences, and the wider humanities to effective pandemic preparedness and response was discussed by Professor Michael Parker, Director of the Ethox Centre, who also expounded upon the important lessons learnt during the COVID-19 pandemic and from recent experiences in Zika and Ebola.

Sir Dave Stuart, MRC Professor of Structural Biology, spoke about the strength in depth of tools accelerating the discovery of new therapeutics that can target viruses with pandemic potential.

Christophe Fraser, Professor of Infectious Disease Epidemiology, discussed what is involved in preventing pandemics, how data sciences can increase the chances of success, and the challenges involved, including deciding which outbreaks to focus on, the importance of early analytics, and community engagement.

Similar stories

Leedham Lab receives funding to improve bowel cancer treatments

The Leedham Lab at the Wellcome Centre for Human Genetics in the Nuffield Department of Medicine (NDM) has been awarded over £2m from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from Nuffield Department of Medicine's Jenner Institute has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

New study provides important insights into TB correlates of protection

Researchers from the Nuffield Department of Medicine’s Jenner Institute have today reported the findings from a study investigating whether previously identified correlates of protection associated with the risk of tuberculosis (TB) disease could also be associated with the risk of infection from the bacteria that causes TB.

Therapeutic HIV vaccine achieves encouraging results

A phase I/IIa clinical trial that the Nuffield Department of Medicine's Jenner Institute collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was temporarily withdrawn.

Prof James Naismith elected as Academy of Medical Sciences' Vice President

Established in 1998, the Academy of Medical Sciences is one of the four UK National Academies, coordinating scholarly research activities and standards in the UK.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.